Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18832560 | 1.00 | KDM4E (0.39) | KDM4ELIPGKDM4CKDM4AKMT2A | |
| SCHEMBL17340953 | 0.89 | KDM4E (0.40) | KDM4ELIPGKDM4CKDM4AKMT2A | |
| SCHEMBL18832578 | 0.89 | KDM4E (0.40) | KDM4ELIPGKDM4CKDM4AKMT2A | |
| SCHEMBL17333984 | 0.84 | CNR1 (0.41) | KDM4ELIPGKDM4CKDM4AALDH1A1 | |
| SCHEMBL17333987 | 0.84 | CNR1 (0.41) | KDM4ELIPGKDM4CKDM4AALDH1A1 | |
| SCHEMBL17333996 | 0.83 | KDM4E (0.37) | KDM4ELIPGKDM4CKDM4AALDH1A1 | |
| SCHEMBL17333994 | 0.83 | KDM4E (0.37) | KDM4ELIPGKDM4CKDM4AALDH1A1 | |
| SCHEMBL18832609 | 0.80 | HTR1D (0.42) | KDM4ELIPGKDM4CKDM4AALDH1A1 | |
| SCHEMBL17340964 | 0.80 | HTR1D (0.42) | KDM4ELIPGKDM4CKDM4AALDH1A1 | |
| SCHEMBL17333932 | 0.80 | KDM4E (0.38) | KDM4ELIPGKDM4CKDM4AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847174-B1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2017-05-17 | — | — | EP | claimed |
| EP-2847174-B1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2847174-B1 | PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9394260-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394260-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150361052-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-17 | — | — | US | disclosed |
| US-20150361052-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361052-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, PNLIP | KDM4E 587/4885LIPG 1/4885KDM4C 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.